obe022

an Oral and Selective Prostaglandin F2alpha Receptor Antagonist

Also Known As:

(S)-2-amino-3-methyl-butyric acid (S)-3-(((S)-3-(biphenyl-4-sulfonyl)-thiazolidine-2-carbonyl)-amino)-3-(4-fluoro-phenyl)-propyl ester

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

1.	Gotteland, Jean-Pierre: 4 articles (01/2020 - 01/2018)
2.	Pohl, Oliver: 4 articles (01/2020 - 01/2018)
3.	Coates, Simon: 3 articles (01/2020 - 11/2018)
4.	Lorch, Ulrike: 3 articles (01/2020 - 11/2018)
5.	Täubel, Jörg: 3 articles (01/2020 - 11/2018)
6.	Marchand, Line: 1 article (01/2019)
7.	Ferber, Georg: 1 article (11/2018)
8.	Fernandes, Sara: 1 article (11/2018)
9.	Foley, Paul: 1 article (11/2018)
10.	Bennett, Phillip R: 1 article (01/2018)

1.	Premature Obstetric Labor (Premature Labor) 01/01/2018 - "OBE022, an Oral and Selective Prostaglandin F2α Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor." 01/01/2020 - "It describes the integration of an early development program of OBE022, a novel, oral, selective prostaglandin F2a receptor antagonist, intended as a treatment for preterm labor, using 2 interdependent, adaptive trial protocols. " 11/01/2018 - "OBE022, a new orally active prostaglandin F2α receptor antagonist (OBE022) with myometrial selectivity is being developed to reduce uterine contractions during preterm labor. "
2.	Headache (Headaches) 01/01/2019 - "Headache and dizziness were the most frequently reported adverse events; dizziness occurred more often with the nifedipine/OBE022 combination. "
3.	Dizziness (Lightheadedness) 01/01/2019 - "Headache and dizziness were the most frequently reported adverse events; dizziness occurred more often with the nifedipine/OBE022 combination. "